High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: Results of the prospective randomized AML2003 trial

Journal of Clinical Oncology

Volumn 31, Issue 17, 2013, Pages 2094-2102

  Schaich, Markus ^a   Parmentier, Stefani ^a   Kramer, Michael ^a   Illmer, Thomas ^a   Stölzel, Friedrich ^a   Röllig, Christoph ^a   Thiede, Christian ^a   Hänel, Mathias ^b   Schäfer Eckart, Kerstin ^b   Aulitzky, Walter ^c   Einsele, Hermann ^d   Ho, Anthony D ^e   Serve, Hubert ^f   Berdel, Wolfgang E ^g   Mayer, Jiri ^l   Schmitz, Norbert ^h   Krause, Stefan W ⁱ   Neubauer, Andreas ^j   Baldus, Claudia D ^k   Schetelig, Johannes ^a   Bornhaüser, Martin ^a   Ehninger, Gerhard ^a   more..

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b KLINIKUM NÜRNBERG   (Germany)

^c ROBERT BOSCH HOSPITAL   (Germany)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f GOETHE UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^h DEPARTMENT OF CARDIOLOGY   (Germany)

ⁱ UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^j UNIVERSITY HOSPITAL MARBURG   (Germany)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^l UNIVERSITY HOSPITAL BRNO   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CYTARABINE; DAUNORUBICIN; MITOXANTRONE; ANTINEOPLASTIC AGENT;

ACUTE MYELOID LEUKEMIA; ADD ON THERAPY; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLEEDING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CONFERENCE PAPER; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HEART DISEASE; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; INTENTION TO TREAT ANALYSIS; LEUKEMIA REMISSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SKIN ALLERGY; TREATMENT OUTCOME; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROSPECTIVE STUDY; REMISSION; SURVIVAL; YOUNG ADULT;

ADOLESCENT; ADULT; AMSACRINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CONSOLIDATION CHEMOTHERAPY; CYTARABINE; DAUNORUBICIN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890459258     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.4743     Document Type: Conference Paper

References (25)

1. Ringdén O, Pavletic SZ, Anasetti C, et al: The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood 113:3110-3118, 2009
2. Levi I, Grotto I, Yerushalmi R, et al: Metaanalysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. Leuk Res 28: 605-612, 2004
3. Büchner T, Berdel WE, Schoch C, et al: Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 24:2480-2489, 2006
4. Cassileth PA, Lynch E, Hines JD, et al: Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79:1924-1930, 1992
5. Döhner H, Estey EH, Amadori S, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010
6. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med 331:896-903, 1994
7. Miyawaki S, Ohtake S, Fujisawa S, et al: A randomized comparison of 4 courses of standarddose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: The JALSG AML201 study. Blood 117:2366-2372, 2011
8. Thomas X, Elhamri M, Raffoux E, et al: Comparison of high-dose cytarabine and timedsequential chemotherapy as consolidation for younger adults with AML in first remission: The ALFA-9802 study. Blood 118:1754-1762, 2011
9. Schaich M, Röllig C, Soucek S, et al: Cytarabine dose of 36 g/m2 compared with 12 g/m2 within first consolidation in acute myeloid leukemia: Results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol 29:2696-2702, 2011
10. Hengeveld M, Suciu S, Karrasch M, et al: Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: Final results of the randomized phase III study (AML 8B) of the European Organisation for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Ann Hematol 91:825-835, 2012
11. Büchner T, Schlenk RF, Schaich M, et al: Acute myeloid leukemia (AML): Different treatment strategies versus a common standard arm-Combined prospective analysis by the German AML Intergroup. J Clin Oncol 30:3604-3610, 2012
12. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003
13. Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-Activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335, 2002
14. Thiede C, Koch S, Creutzig E, et al: Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107:4011-4020, 2006
15. Moore JO, George SL, Dodge RK, et al: Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood 105:3420-3427, 2005
16. Schlenk RF, Döhner K, Mack S, et al: Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 28:4642-4648, 2010
17. Stelljes M, Beelen DW, Braess J, et al: Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: Landmark analysis from a single prospective multicenter trial. Haematologica 96:972-979, 2011
18. Burnett AK, Hills RK, Milligan D, et al: Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial. J Clin Oncol 29:369-377, 2011
19. Brune M, Castaigne S, Catalano J, et al: Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: Results of a randomized phase 3 trial. Blood 108:88-96, 2006
20. Löwenberg B, Pabst T, Vellenga E, et al: Cytarabine dose for acute myeloid leukemia. N Engl J Med 364:1027-1036, 2011
21. Bradstock KF, Matthews JP, Lowenthal RM, et al: A randomized trial of high-versus conventional-dosecytarabineinconsolidationchemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 105:481-488, 2005
22. Cassileth PA, Harrington DP, Appelbaum FR, et al: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339:1649-1656, 1998
23. Pfirrmann M, Ehninger G, Thiede C, et al: Prediction of post-remission survival in acute myeloid leukaemia: A post-hoc analysis of the AML96 trial. Lancet Oncol 13:207-214, 2012
24. Krönke J, Schlenk RF, Jensen KO, et al: Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: A study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol 29:2709-2716, 2011
25. Maurillo L, Buccisano F, Del Principe MI, et al: Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 26:4944-4951, 2008